Crystal structures of two aminoglycoside kinases bound with a Eukaryotic protein kinase inhibitor

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Fong, Desiree H ^a   Xiong, Bing ^a,b   Hwang, Jiyoung ^a,c   Berghuis, Albert M ^a  

^a MCGILL UNIVERSITY   (Canada)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE 3' PHOSPHOTRANSFERASE IIIA; AMINOGLYCOSIDE 9 PHOSPHOTRANSFERASE IA; BACTERIAL ENZYME; CASEIN KINASE I; N (2 AMINOETHYL) 5 CHLORO ISOQUINOLINE 8 SULFONAMIDE; PHOSPHOTRANSFERASE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; ISOQUINOLINE DERIVATIVE; KANAMYCIN KINASE; N (2 AMINOETHYL) 5 CHLOROISOQUINOLINE 8 SULFONAMIDE; N-(2-AMINOETHYL)-5-CHLOROISOQUINOLINE-8-SULFONAMIDE; NUCLEOTIDE; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ANTIBIOTIC RESISTANCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG BINDING SITE; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; NUCLEOTIDE BINDING SITE; BINDING SITE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; EUKARYOTIC CELL; METABOLISM; PROTEIN BINDING; X RAY CRYSTALLOGRAPHY;

BACTERIA (MICROORGANISMS); EUKARYOTA;

ADJUVANTS, PHARMACEUTIC; BINDING SITES; CASEIN KINASE I; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; EUKARYOTIC CELLS; ISOQUINOLINES; KANAMYCIN KINASE; NUCLEOTIDES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN BINDING; PROTEIN KINASE INHIBITORS;

EID: 79955847725     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019589     Document Type: Article

References (42)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, et al. (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 48: 1-12.
2. De Pascale G, Wright GD, (2010) Antibiotic resistance by enzyme inactivation: from mechanisms to solutions. Chembiochem 11: 1325-1334.
3. Therrien C, Levesque RC, (2000) Molecular basis of antibiotic resistance and beta-lactamase inhibition by mechanism-based inactivators: perspectives and future directions. FEMS Microbiol Rev 24: 251-262.
4. Shaw KJ, Rather PN, Hare RS, Miller GH, (1993) Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 57: 138-163.
5. Burk DL, Berghuis AM, (2002) Protein kinase inhibitors and antibiotic resistance. Pharmacol Ther 93: 283-292.
6. Gao F, Yan X, Shakya T, Baettig OM, Ait-Mohand-Brunet S, et al. (2006) Synthesis and structure-activity relationships of truncated bisubstrate inhibitors of aminoglycoside 6′-N-acetyltransferases. J Med Chem 49: 5273-5281.
7. Vakulenko SB, Mobashery S, (2003) Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 16: 430-450.
8. Hon WC, McKay GA, Thompson PR, Sweet RM, Yang DS, et al. (1997) Structure of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic protein kinases. Cell 89: 887-895.
9. Daigle DM, McKay GA, Wright GD, (1997) Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors. J Biol Chem 272: 24755-24758.
10. Fong DH, Berghuis AM, (2002) Substrate promiscuity of an aminoglycoside antibiotic resistance enzyme via target mimicry. Embo J 21: 2323-2331.
11. Fong DH, Lemke CT, Hwang J, Xiong B, Berghuis AM, (2010) Structure of the Antibiotic Resistance Factor Spectinomycin Phosphotransferase from Legionella pneumophila. J Biol Chem 285: 9545-9555.
12. Nurizzo D, Shewry SC, Perlin MH, Brown SA, Dholakia JN, et al. (2003) The crystal structure of aminoglycoside-3′-phosphotransferase-IIa, an enzyme responsible for antibiotic resistance. J Mol Biol 327: 491-506.
13. Young PG, Walanj R, Lakshmi V, Byrnes LJ, Metcalf P, et al. (2009) The crystal structures of substrate and nucleotide complexes of Enterococcus faecium aminoglycoside-2″-phosphotransferase-IIa [APH(2″)-IIa] provide insights into substrate selectivity in the APH(2″) subfamily. J Bacteriol 191: 4133-4143.
14. Toth M, Frase H, Antunes NT, Smith CA, Vakulenko SB, (2010) Crystal structure and kinetic mechanism of aminoglycoside phosphotransferase-2″-IVa. Protein Sci 19: 1565-1576.
15. Daigle DM, McKay GA, Thompson PR, Wright GD, (1999) Aminoglycoside antibiotic phosphotransferases are also serine protein kinases. Chem Biol 6: 11-18.
16. McKay GA, Thompson PR, Wright GD, (1994) Broad spectrum aminoglycoside phosphotransferase type III from Enterococcus: overexpression, purification, and substrate specificity. Biochemistry 33: 6936-6944.
17. McKay GA, Wright GD, (1995) Kinetic mechanism of aminoglycoside phosphotransferase type IIIa. Evidence for a Theorell-Chance mechanism. J Biol Chem 270: 24686-24692.
18. Thompson PR, Hughes DW, Wright GD, (1996) Mechanism of aminoglycoside 3′-phosphotransferase type IIIa: His188 is not a phosphate-accepting residue. Chem Biol 3: 747-755.
19. Thompson PR, Schwartzenhauer J, Hughes DW, Berghuis AM, Wright GD, (1999) The COOH terminus of aminoglycoside phosphotransferase (3′)-IIIa is critical for antibiotic recognition and resistance. J Biol Chem 274: 30697-30706.
20. Burk DL, Hon WC, Leung AK-W, Berghuis AM, (2001) Structural analyses of nucleotide binding to an aminoglycoside phosphotransferase. Biochemistry 40: 8756-8764.
21. Fong DH, Berghuis AM, (2009) Structural basis of APH(3′)-IIIa-mediated resistance to N1-substituted aminoglycoside antibiotics. Antimicrob Agents Chemother 53: 3049-3055.
22. Chijiwa T, Hagiwara M, Hidaka H, (1989) A newly synthesized selective casein kinase I inhibitor, N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis. J Biol Chem 264: 4924-4927.
23. Cherry M, Williams DH, (2004) Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. Curr Med Chem 11: 663-673.
24. Liao JJ, (2007) Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 50: 409-424.
25. Xu RM, Carmel G, Kuret J, Cheng X, (1996) Structural basis for selectivity of the isoquinoline sulfonamide family of protein kinase inhibitors. Proc Natl Acad Sci U S A 93: 6308-6313.
26. Sowadski JM, Epstein LF, Lankiewicz L, Karlsson R, (1999) Conformational diversity of catalytic cores of protein kinases. Pharmacol Ther 82: 157-164.
27. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y, (1984) Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23: 5036-5041.
28. Rena G, Bain J, Elliott M, Cohen P, (2004) D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep 5: 60-65.
29. Huang D, Zhou T, Lafleur K, Nevado C, Caflisch A, (2010) Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Bioinformatics 26: 198-204.
30. Akritopoulou-Zanze I, Hajduk PJ, (2009) Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov Today 14: 291-297.
31. Johnson LN, (2009) Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 42: 1-40.
32. Fong DH, Berghuis AM, (2004) Crystallization and preliminary crystallographic analysis of 3′-aminoglycoside kinase type IIIa complexed with a eukaryotic protein kinase inhibitor, CKI-7. Acta Crystallogr D Biol Crystallogr 60: 1897-1899.
33. Lemke CT, Hwang J, Xiong B, Cianciotto NP, Berghuis AM, (2005) Crystallization and preliminary crystallographic analysis of an aminoglycoside kinase from Legionella pneumophila. Acta Crystallogr Sect F Struct Biol Cryst Commun 61: 606-608.
34. Otwinowski Z, Minor W, (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276: 307-326.
35. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54: 905-921.
36. Allinger NL, (1977) Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. Journal of American Chemical Society 99: 8127-8134.
37. Burkert U, Allinger NL, (1982) Molecular Mechanics. Washington, D.C. American Chemical Society.
38. Jones TA, Zou J-Y, Cowan SW, Kjeldgaard M, (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47: 110-119.
39. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221.
40. Emsley P, Lohkamp B, Scott WG, Cowtan K, (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66: 486-501.
41. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ, (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61: 458-464.
42. Collaborative Computational Project Number 4 (1994) The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr D50: 760-763.